Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

927
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
927
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

752
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
752
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.4K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.6K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forensic postmortem examination as sentinel evidence of rifampicin-resistant tuberculosis outside routine clinical reporting.

IJID regions·2026
Same author

Comparison of Environmental Microbiomes, Resistomes and Plasmidomes from a Human Tertiary Hospital and Companion Animal Veterinary Hospital in London, UK.

Antibiotics (Basel, Switzerland)·2026
Same author

Use of hollow fiber systems to model treatment of infections: A practical guide.

iScience·2026
Same author

Autochthonous dengue transmission in Europe: epidemiology, mechanisms, and modelling insights.

Biology direct·2026
Same author

The effects of feeding guild, seasonality, and warming on the gut microbiomes of Antarctic echinoderms.

BMC microbiology·2026
Same author

Gut microbiome disruption in Tanzanian pulmonary tuberculosis patients: links to treatment, nutritional status, and host immunity.

BMC microbiology·2026
Same journal

Probing Cinnamamides and Benzamides as Anthelmintics: Discovery of Potent Drug-Like Agents Against Angiostrongylus cantonensis.

Chemical biology & drug design·2026
Same journal

Perfluorooctane Sulfonate Exposure and Peripheral Artery Disease: Mendelian Randomization and Integrative Multi-Omics Systems Toxicology With Machine Learning.

Chemical biology & drug design·2026
Same journal

In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia-Telangiectasia.

Chemical biology & drug design·2026
Same journal

Synthesis of Peptide Analogs From Fish Venom With Potential Antimicrobial and Anticancer Activity.

Chemical biology & drug design·2026
Same journal

Design, Optimization and Mechanistic Insights Into Terpenoid-Derived Inhibitors of Protein Kinase C Iota.

Chemical biology & drug design·2026
Same journal

Design, Synthesis, and In Vitro Biological Assessment of Novel Benzimidazole and Hydrazone Derivatives Against Pancreatic Cancer and Melanoma Cells.

Chemical biology & drug design·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K

Improving the tuberculosis drug development pipeline.

Dimitrios Evangelopoulos1, Timothy D McHugh1

  • 1Centre for Clinical Microbiology, University College London, London, NW3 2PF, UK.

Chemical Biology & Drug Design
|March 17, 2015
PubMed
Summary
This summary is machine-generated.

Developing new treatments for multidrug-resistant tuberculosis is crucial. This review explores challenges in Mycobacterium tuberculosis drug discovery and suggests future therapeutic strategies.

Keywords:
biological screeningdrug developmentgene expressionmechanism-based drug designtherapeutic target

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Related Experiment Videos

Last Updated: Apr 16, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Mycobacterium tuberculosis is a highly successful pathogen.
  • Multidrug-resistant tuberculosis necessitates novel therapeutic agents.
  • The complex intracellular lifestyle of M. tuberculosis hinders drug development.

Purpose of the Study:

  • To review the challenges in tuberculosis drug discovery.
  • To highlight current solutions and future directions for TB therapeutics.
  • To explore alternative approaches for developing new anti-TB drugs.

Main Methods:

  • Literature review of current tuberculosis drug development pipeline.
  • Analysis of factors complicating M. tuberculosis drug discovery.
  • Synthesis of existing and proposed therapeutic strategies.

Main Results:

  • Several new molecules are in clinical trials for tuberculosis.
  • The intracellular survival mechanisms of M. tuberculosis pose significant challenges.
  • Innovative approaches are needed to overcome drug resistance.

Conclusions:

  • Tuberculosis drug discovery is complex but progressing.
  • Future research should focus on novel targets and alternative strategies.
  • Overcoming drug resistance requires a multifaceted approach.